Abstract

Reports of urticaria and rash with bupropion are common, with an estimated incidence of 1-4%. Serious adverse reactions, including seizures and angioedema occur less commonly, but may be dose related. Rarely patients present with fever, arthralgia and myalgia resembling a serumsickness reaction. A case of a 30 year-old man presenting with a rash, angioedema, and arthralgia 19 days after commencing bupropion treatment to aid smoking cessation is described. Treatment with antihistamines and steroids, resulted in improvement within 3 hours, and complete resolution after 3 days. Management also included identifying and discontinuing the causative agent. Recent concerns over neuropsychiatric side effects of bupropion are highlighted. The literature is reviewed and recommendations for safer prescribing discussed.
[download-attachments container="div" style="list" dipslay_icon="1" display_count="1" display__size="0"]

References

1. Dwoskin LP, Rauhut AS. Review of the Pharmacology and Clinical Profile of Bupropion, an Antidepressant and Tobacco Use Cessation Agent. CNS Drug Reviews 2006; 12(3): 178–207.
2. Beyens MN, Guy C, Mounier G et al. Serious adverse reactions of bupropion for smoking cessation: analysis of the French Pharmacovigilance Database
   from 2001 to 2004. Drug Saf. 2008; 31(11): 1017–26.
3. Kaplan AP, Greaves MW. Angioedema. Journal of the American Academy of Dermatology 2006; 53(3): 373–388.
4. McCollom RA, Elbe DH, Ritchie AH. Bupropion-induced serum sickness-like reaction. Ann Pharmacother. 2000; 34(4): 471–3.
5. Toncic RJ, Marinovic B. Nonallergic Hypersensitivity to Nonsteroidal Antiinflammatory Drugs, Angiotensin-Converting Enzyme Inhibitors, Radiocontrast Media, Local Anesthetics, Volume Substitutes and Medications used in General Anesthesia. Acta Dermaovenerol Croat. 2009; 17(1): 54–69.
6. Tackett AE, Smith KM Bupropion-induced angioedema. Am J Health Syst Pharm 2008; 65(17): 1627–30.
7. Bupropion (Zyban): Patient UK Leaflet. EMIS 2009; Doc ID 4544, Version 39.
8. Medication Guide: Zyban (bupropion hydrochloride) Sustained-Release Tablets. GlaxoSmithkline 2009; NDA 20-711/S-032. Approved by the U.S. Food and Drug Administration.
9. British National Formulary 55. March 2008.
10. Wooltorton E. Bupropion (Zyban, Wellbutrin SR): reports of deaths, seizures, serum sickness. JAMC 2002; 166(1): 68
11. Humayun F, Shehab TM, Tworek JA. A fatal case of bupropion (Zyban) hepatotoxicity with autoimmune features: Case report. Journal of Medical Case Reports 2007; 1: 88.